# Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

> **NCT05372939** · PHASE2 · COMPLETED · sponsor: **Applied Molecular Transport** · enrollment: 51 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** AMT-101 (oral)
- **OTHER:** Placebo (oral)
- **COMBINATION_PRODUCT:** Humira (adalimumab)

## Key facts

- **NCT ID:** NCT05372939
- **Lead sponsor:** Applied Molecular Transport
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-05
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-07-13
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372939, "Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05372939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*